CFO
CRL icon

CVA Family Office’s Charles River Laboratories CRL Stock Holding History

CVA Family Office’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9K Buy
145
+12
+9% +$2.14K ﹤0.01% 696
2026
Q1 		$22.9K Buy
133
+51
+62% +$9.46K ﹤0.01% 768
2025
Q4 		$16.4K Hold
82
– – ﹤0.01% 723
2025
Q3 		$12.8K Hold
82
– – ﹤0.01% 764
2025
Q2 		$12.4K Sell
82
-29
-26% -$3.87K ﹤0.01% 765
2025
Q1 		$16.7K Buy
111
+70
+171% +$11.7K ﹤0.01% 712
2024
Q4 		$7.57K Sell
41
-12
-23% -$2.31K ﹤0.01% 830
2024
Q3 		$10.4K Sell
53
-45
-46% -$9.35K ﹤0.01% 752
2024
Q2 		$20.2K Hold
98
– – ﹤0.01% 634
2024
Q1 		$26.6K Hold
98
– – ﹤0.01% 595
2023
Q4 		$23.2K Buy
+98
New +$19.3K ﹤0.01% 600
2023
Q3 		– Sell
-242
Closed -$50.9K – 387
2023
Q2 		$50.9K Buy
242
+144
+147% +$28.7K 0.01% 448
2023
Q1 		$19.8K Hold
98
– – ﹤0.01% 594
2022
Q4 		$21.4K Hold
98
– – 0.01% 552
2022
Q3 		$19K Buy
98
+60
+158% +$13K 0.01% 533
2022
Q2 		$8K Sell
38
-25
-40% -$6.11K ﹤0.01% 670
2022
Q1 		$18K Sell
63
-45
-42% -$13.9K ﹤0.01% 579
2021
Q4 		$41K Buy
108
+53
+96% +$20.6K 0.01% 393
2021
Q3 		$12K Sell
55
-68
-55% -$28.2K 0.01% 285
2021
Q2 		$46K Buy
123
+85
+224% +$28.4K 0.01% 378
2021
Q1 		$11K Buy
+38
New +$10.6K ﹤0.01% 509
2020
Q4 		– Sell
-55
Closed -$12K – 357
2020
Q3 		$12K Buy
+55
New +$11.4K 0.01% 285

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

CVA Family Office's CRL Position: Q2 2026 in Review

CVA Family Office increased its Charles River Laboratories (CRL) stake by 9% in Q2 2026, buying an estimated $2.14K and bringing the position to 145 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

CVA Family Office first reported a position in CRL in Q3 2020 and has held it in 22 quarters since. The position peaked at $50.9K in Q2 2023. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • CVA Family Office held 145 shares of Charles River Laboratories worth $32.9K as of Q2 2026.
  • CVA Family Office bought 12 Charles River Laboratories shares in Q2 2026, an estimated $2.14K.
  • Charles River Laboratories made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #696 holding.
  • CVA Family Office first reported a position in Charles River Laboratories in Q3 2020 and has held it in 22 quarters since.
  • CVA Family Office's Charles River Laboratories position peaked at $50.9K in Q2 2023.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.